<DOC>
	<DOCNO>NCT02071069</DOCNO>
	<brief_summary>1 . To evaluate efficacy , safety , feasibility maintenance therapy Cetuximab combine irinotecan fluorouracil Cetuximab plus irinotecan fluorouracil ( FOLFIRI ) patient incurable colorectal cancer . 2 . The relevant phase III study report progression free-survival cetuximab combine FOLFIRI advance colorectal cancer 4.3 month 6.8 month . This study assume progression free-survival 5.1 month inferior continuous chemotherapy</brief_summary>
	<brief_title>Efficacy Tolerance Maintenance Therapy Patients With Incurable Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients age ≥18 year histologically confirm metastatic colorectal cancer 2 . Eastern Cooperative Oncology Group performance status ≤2 3. life expectancy &gt; 3 month enrol . 4 . All patient least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST , version 1.1 ) 5 . None previous exposure Cetuximab irinotecan . 6 . Patients adequate haematological ( absolute neutrophil count &gt; 1.5 × 109/l ; platelet count &gt; 100 × 109/l ; haemoglobin &gt; 9 g/dl ) , hepatic [ total bilirubin &lt; 1.5 × upper limit normal ( ULN ) ; alanine aminotransferase aspartate aminotransferase &lt; 2.5 × ULN , &lt; 5 × ULN case hepatic metastasis &lt; 10 × ULN case osseous metastasis ; alkaline phosphatase &lt; 2.5 × ULN , &lt; 5 × ULN &lt; 10 × ULN case hepatic osseous metastasis , respectively ] renal function ( creatinine clearance ≥60 ml/min ) 7 . All RAS wildtype . 1 . Pregnant breastfeeding woman ; 2 . Clinically significant cardiac disease ; 3 . Lack physical integrity upper gastrointestinal tract ; 4 . History malignancy ; 5 . Central nervous system metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Incurable colorectal cancer</keyword>
	<keyword>maintenance therapy</keyword>
	<keyword>Cetuximab</keyword>
</DOC>